Phico Therapeutics Awarded up to $18.2 Million USD (c.£13.2 Million GBP) CARB-X Funding to Advance SASPject Antibacterial Therapy Through Phase 1 Clinical Trials

• Funding will support first-in-man intravenous studies to tackle antibiotic resistant Pseudomonas aeruginosa in ventilated associated pneumonia
• $5.3 million USD (c.£3.8 million GBP) first grant followed by up to $12.9 million USD (c.£9.4 million GBP) in milestone payments

CAMBRIDGE, England--(BUSINESS WIRE)-- Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. The funding will support the progression of Phico’s lead product SASPject™ PT3.9 through clinical trials with $5.3 million USD (circa. £3.8 million GBP) available immediately and a further $12.9 million (circa. £9.4 million GBP) contingent on reaching specific project milestones.

SASPject PT3.9 has been developed for the intravenous treatment of hospital infections caused by, Pseudomonas aeruginosa using Phico’s SASPject platform. The platform utilises unique antibacterial small acid-soluble spore proteins (SASP), targeting selected bacterial species to inactivate bacterial DNA, stopping them from metabolising or reproducing. The Phase I clinical trials will be first-in-man, intravenous studies, focusing on establishing the safety and kinetics of PT3.9 in healthy volunteers and, potentially, patients with ventilated hospital acquired pneumonia and ventilator associated pneumonia.

P. aeruginosa is a leading cause of pneumonia in hospital patients, especially those on ventilators. The increasing incidence of strains showing multi-drug antibiotic resistance resulted in the U.S. Centers for Disease Control and Prevention classifying P. aeruginosa as a serious threat to human health. With antimicrobial resistance also listed as a Top 3 Global Health Threat by the World Health Organisation, the SASPject platform could provide a new range of antibiotic treatments to help overcome this challenge.

Dr. Heather Fairhead, Phico Founder and CEO said: “To receive funding from CARB-X is important validation for our SASPject technology platform and its potential in fighting bacterial resistance. It has been awarded at the end of a thorough due diligence process which reinforces the credibility of the company and our team. I am delighted to now look forward to progressing our lead product to clinical trials and developing a product pipeline that will advance the science of antibacterial therapy and in time, save millions of lives round the world.”

“Phico’s innovative approach delivers the antibiotic effect of SASPs by using engineered bacteriophages to precisely target P. aeruginosa infections in the lungs,” said Erin Duffy, R&D Chief of CARB-X. “This approach has the potential to target bacteria without damaging other cells, and without contributing to the rise of resistance. If successful, this new intravenous drug could transform the way patients with ventilator-associated pneumonia are treated in hospitals, and save lives.”

More information: www.phicotx.co.uk

View Phico’s SASPject technology: https://www.youtube.com/watch?v=U27YARVMtkg

View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005338/en/